ASX Today, page-80

mY rationale is that when we get to year 3 orders from Labcon will $20-25m 1-year forward. Add another $5-10m from other OEMs you have $30-35m in sales in 2.5-3 years.

At that pace this is not valued on PE but on P/sales as this is exponentially growing.. 20-30x is the norm.. so you come with a valuation of $500-750m .. thats not assuming a lot from OEMs when most pharma cos will start paying attention now... then the food companies.. and they already have dozens of potential cos in talks..

everyone willl have. a view but we are only scratching the surface on what will have sales in the hundreds of millions in the long run..

This will be a buck per share.. just. a matter if its in 2, 3 or 5 years. Im optimistic but pragmatic that execution remains the key aspect. And that has been solid for the past 2 years.